An effective patient-supporting intervention for topical treatment of psoriasis is also cost-effective

This study provides an economic evaluation of a randomized controlled psoriasis trial providing regular long-term support delivered by dermatology nurses. The incremental costs were estimated at & POUND;462, with an average increase of 0.08 quality-adjusted life-years (QALYs) per patient for participants receiving the support compared with those receiving standard care. The incremental cost-effectiveness ratio for patients was & POUND;5999/QALY. The intervention had an almost 100% probability of being cost-effective at a willingness-to-pay threshold of & POUND;30 000 per QALY. Background A randomized controlled trial (RCT) of topical treatment combined with regular patient support provided by dermatological nurses in structured consultations of 20-min duration every fourth week improved psoriasis severity, quality of life and treatment adherence compared with topical treatment combined with standard patient support, which is seeing a dermatologist every third month.Objectives To examine the economic impact of the patient support from a healthcare-sector perspective in the RCT.Methods Costs for primary care, secondary healthcare services and costs of prescription medication were compared for the intervention and nonintervention groups over 48 weeks. Health benefits were expressed in terms of quality-adjusted life-years (QALYs) measured by the EuroQoL five-dimension three-level questionnaire. Regression analyses were used to estimate incremental cost and QALYs.Results The incremental cost was estimated at & POUND;462, with an average increase of 0.08 QALYs per patients for participants receiving the intervention compared with those receiving standard care. The incremental cost-effectiveness ratio for patients was & POUND;5999/QALY. The intervention had an almost 100% probability of being cost-effective at a willingness-to-pay threshold of & POUND;30 000 per QALY.Conclusions Addressing adherence issues is critical to improving outcomes for patients with psoriasis who use topical treatment. The personal support intervention was effective with an acceptable increase in costs.